CELLDEX THERAPEUTICS INC NEW - COM (CLDX)

CUSIP: 15117B103

Q4 2018 13F Holders as of 31 Dec 2018

Type / Class
Equity / COM
Total 13F shares
50,935,481
Share change
-3,811,997
Total reported value
$10,079,985
Put/Call ratio
0%
Price per share
$0.20
Number of holders
61
Value change
-$1,170,208
Number of buys
19
Number of sells
37

Quarterly Holders Quick Answers

What is CUSIP 15117B103?
CUSIP 15117B103 identifies CLDX - CELLDEX THERAPEUTICS INC NEW - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of CELLDEX THERAPEUTICS INC NEW - COM (CLDX) as of Q4 2018

As of 31 Dec 2018, CELLDEX THERAPEUTICS INC NEW - COM (CLDX) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 50,935,481 shares. The largest 10 holders included KLP Enterprises, LLC, Cresset Asset Management, LLC, RENAISSANCE TECHNOLOGIES LLC, Meditor Group Ltd, Vanguard Group Inc, DIMENSIONAL FUND ADVISORS LP, BlackRock Inc., TWO SIGMA INVESTMENTS, LP, ACADIAN ASSET MANAGEMENT LLC, and DEUTSCHE BANK AG\. This page lists 61 institutional shareholders reporting positions in this security for the Q4 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.